NCT03230721

Brief Summary

Today, endoscopic enucleation of the prostate (EEP) has been recognized a method of choice for treatment of benign prostatic hyperplasia (BPH) of any size, including large-sized glands (\>80 cc). The goal of our study was to compare perioperative efficacy, functional outcomes and safety of different techniques of endoscopic enucleation of the prostate (monopolar enucleation, holmium laser enucleation, thulium laser enucleation) in a single center.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
450

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2015

Typical duration for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 15, 2015

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 22, 2017

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 21, 2017

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

July 24, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 26, 2017

Completed
Last Updated

July 28, 2017

Status Verified

July 1, 2017

Enrollment Period

2.3 years

First QC Date

July 24, 2017

Last Update Submit

July 26, 2017

Conditions

Keywords

laserHoLEPThuLEPThuliumThulium-fiberBPHEEPmonopolar enucleation

Outcome Measures

Primary Outcomes (1)

  • IPSS

    International Prostate Symptom Score

    Six months

Secondary Outcomes (4)

  • QoL

    Six months

  • PVR

    Six months

  • Qmax

    Six months

  • IIEF-5

    Six months

Study Arms (3)

ThuLEP group

ACTIVE COMPARATOR

Patients who underwent thulium-fiber laser enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.

Procedure: Thulium-fiber laser enucleation of the prostate

Monopolar enucleation group

ACTIVE COMPARATOR

Patients who underwent monopolar enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.

Procedure: Monopolar enucleation of the prostate

HoLEP group

ACTIVE COMPARATOR

Patients who underwent Ho:YAG laser enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.

Procedure: Ho:YAG laser enucleation of the prostate

Interventions

A high-power (120 W) thulium fiber laser (Urolase, IPG IRE-POLUS, Russia) with wavelength of 1940 nm was used for thulium laser enucleation. In our study, we used a 600-μm laser fiber. The operations were performed at power of 60 W energy of 1.5 J and repetition rate of 40 Hz. Laser power in the verumontanum zone was decreased to 30 W and repetition rate to 20 Hz.

Also known as: ThuLEP
ThuLEP group

Monopolar enucleation was performed with a high-frequency generator (50-60 Hz), a pusher-electrode, and a hook-electrode.

Also known as: Monopolar enucleation
Monopolar enucleation group

Holmium laser enucleation of prostatic hyperplasia was performed with a 100 W laser (VersaPulse Powersuite 100, Lumenis, USA/Israel) with wavelength of 2100 nm and 550-μm fiber at the tip. The operation was performed at power of 70 W; it was decreased to 40 W when incisions were made at the verumontanum.

Also known as: HoLEP
HoLEP group

Eligibility Criteria

Age50 Years - 90 Years
Sexmale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • IPSS\>20;
  • maximum urinary flow rate\< 10ml\\s (Qmax);
  • ineffective alfa-blockers therapy.

You may not qualify if:

  • histologically verified prostate cancer;
  • history of prostatic surgery;
  • urethral strictures;
  • bladder stones;
  • chronic urinary retention and cystostomy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (3)

  • Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KAO, Gravas S. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol. 2015 Jun;67(6):1099-1109. doi: 10.1016/j.eururo.2014.12.038. Epub 2015 Jan 19.

    PMID: 25613154BACKGROUND
  • Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, McVary K, Novara G, Woo H, Madersbacher S. A Systematic Review and Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic Obstruction: An Update. Eur Urol. 2015 Jun;67(6):1066-1096. doi: 10.1016/j.eururo.2014.06.017. Epub 2014 Jun 25.

    PMID: 24972732BACKGROUND
  • Glybochko PV, Rapoport LM, Enikeev ME, Enikeev DV. Holmium laser enucleation of the prostate (HoLEP) for small, large and giant prostatic hyperplasia: tips and tricks. Urologia. 2017 Aug 1;84(3):169-173. doi: 10.5301/uj.5000232. Epub 2017 May 10.

    PMID: 28497447BACKGROUND

MeSH Terms

Conditions

Prostatic HyperplasiaLower Urinary Tract Symptoms

Condition Hierarchy (Ancestors)

Prostatic DiseasesGenital Diseases, MaleGenital DiseasesUrogenital DiseasesMale Urogenital DiseasesUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Dmitry Enikeev, MD, PhD

    I.M. Sechenov First Moscow State Medical University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Deputy Director for Sсience, Dept. of Urology, I.M. Sechenov Moscow State Medical University

Study Record Dates

First Submitted

July 24, 2017

First Posted

July 26, 2017

Study Start

January 15, 2015

Primary Completion

April 22, 2017

Study Completion

July 21, 2017

Last Updated

July 28, 2017

Record last verified: 2017-07

Data Sharing

IPD Sharing
Will not share